CPRC
ROIV icon

Consolidated Portfolio Review Corp’s Roivant Sciences ROIV Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.79M Hold
276,530
– – 0.82% 17
2026
Q1 		$7.66M Hold
276,530
– – 0.7% 19
2025
Q4 		$6M Buy
+276,530
New +$5.46M 0.52% 21

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Consolidated Portfolio Review Corp's ROIV Position: Q2 2026 in Review

Consolidated Portfolio Review Corp held its Roivant Sciences (ROIV) position steady in Q2 2026 at 276,530 shares worth $9.79M. The position accounts for 0.82% of the portfolio, ranked #17.

Consolidated Portfolio Review Corp first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Consolidated Portfolio Review Corp held 276,530 shares of Roivant Sciences worth $9.79M as of Q2 2026.
  • Consolidated Portfolio Review Corp left its Roivant Sciences share count unchanged in Q2 2026.
  • Roivant Sciences made up 0.82% of Consolidated Portfolio Review Corp's portfolio in Q2 2026, its #17 holding.
  • Consolidated Portfolio Review Corp first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Consolidated Portfolio Review Corp's 13F filing for Q2 2026, filed 23 Jul 2026.